Kommisjonens gjennomføringsforordning (EU) 2024/2101 av 30. juli 2024 om tillatelse til å bringe olje av Schizochytrium sp. (CABIO-A-2) i omsetning som et nytt næringsmiddel og endring av gjennomføringsforordning (EU) 2017/2470
Godkjenning av olje av Schizochytrium sp. som ny mat
Kommisjonsforordning publisert i EU-tidende 31.7.2024
Tidligere
- Utkast til kommisjonsforordning godkjent av komite (representanter for medlemslandene) og publisert i EUs komitologiregister 21.5.2024
Nærmere omtale
BAKGRUNN (fra kommisjonsforordnignen)
(1) Regulation (EU) 2015/2283 provides that only novel foods authorised and included in the Union list of novel foods may be placed on the market within the Union.
(2) Pursuant to Article 8 of Regulation (EU) 2015/2283, Commission Implementing Regulation (EU) 2017/2470 has established a Union list of novel foods.
(3) On 19 March 2021, the company CABIO Biotech (Wuhan) Co., Ltd. (‘the applicant’) submitted an application for an authorisation to the Commission in accordance with Article 10(1) of Regulation (EU) 2015/2283 to place Schizochytrium sp. (CABIO-A-2) oil on the Union market as a novel food. The applicant requested for the novel food to be authorised for use in infant formula and follow-on formula as defined in Regulation (EU) No 609/2013 of the European Parliament and of the Council . The strain of Schizochytrium sp. used by the applicant and concerned by this application is specified as strain CABIO-A-2.
(4) On 12 July 2021, the Commission requested the European Food Safety Authority (ʽthe Authorityʼ) to carry out an assessment of Schizochytrium sp. (CABIO-A-2) oil as a novel food.
(5) On 26 October 2023, the Authority adopted its scientific opinion on the ‘Safety of oil from Schizochytrium sp. (strain CABIO-A-2) for use in infant and follow-on formula as a novel food pursuant to Regulation (EU) 2015/2283’ in accordance with Article 11 of Regulation (EU) 2015/2283.
(6) In its scientific opinion, the Authority concluded that the novel food, oil produced from the strain CABIO-A-2 of the microalgae Schizochytrium sp., is safe under the proposed conditions of use. The Authority noted, that as the proposed use levels are in accordance with Regulation (EU) No 609/2013 and its supplementing Regulation (EU) 2016/127 , the intake of docosahexaenoic acid (DHA) from infant formula and follow on formula containing the novel food at the proposed use levels is within the range foreseen by that Regulation. Therefore, that scientific opinion gives sufficient grounds to establish that Schizochytrium sp. (CABIO-A-2) oil, when used under the proposed conditions of use, fulfils the conditions for its placing on the market in accordance with Article 12(1) of Regulation (EU) 2015/2283. It is appropriate that the inclusion of Schizochytrium sp. (CABIO-A-2) oil as a novel food in the Union list of novel foods contains the information referred to in Article 9(3) of Regulation (EU) 2015/2283.
(7) Schizochytrium sp. (CABIO-A-2) oil should be included in the Union list of novel foods set out in Implementing Regulation (EU) 2017/2470. The Annex to Implementing Regulation (EU) 2017/2470 should therefore be amended accordingly.
(8) The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Plants, Animals, Food and Feed,